Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Key PointsArgenx's top and bottom lines are growing robustly.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at nasdaq.com →

More in Finance & Markets

More from Wednesday 2 September →